BCYC · Bicycle Therapeutics PLC · Executive Compensation
Market Cap
$253.74M
Shares
70.09M
Volume · Nov 3
81.49K
Avg daily vol (3M)
409.69K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Kevin Lee | Ph.D., MBA Chief Executive Officer | $4,376,296 |
| Lee Kalowski | Chief Financial Officer and President | $2,481,133 |
| Michael Skynner | Chief Operating Officer | $1,818,129 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Kevin Lee | Ph.D., MBA Chief Executive Officer | $817,894 |
| Lee Kalowski | Chief Financial Officer and President | $520,056 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Charles Swanton | Class II director of the Board of Directors | Resigned | 2026-08-20 |
| Jennifer Perry | Chief Operating Officer | Appointed | 2026-03-17 |
| Travis Thompson | Chief Financial Officer | Appointed | 2026-02-03 |
| Hervé Hoppenot | Class I director | Appointed | 2025-09-08 |
| Roger Dansey, M.D. | Class III director | Appointed | 2025-09-08 |
| Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP | Director | Appointed | 2025-08-08 |
| Fabrice André, M.D., Ph.D. | Clinical Advisory Board member | Appointed | 2025-03-27 |
| Eric Westin, M.D. | chief medical officer | Appointed | 2025-03-27 |
| Jim MacDonald-Clink | senior vice president, head of business development | Appointed | 2025-03-27 |
| Santiago Arroyo, M.D., Ph.D. | Chief Development Officer | Resigned | 2025-03-27 |
| Richard Kender | Director | Retired | 2025-03-27 |
| Felix J. Baker, Ph.D. | Chairman of the Board of Directors | Appointed | 2025-03-27 |
| Pierre Legault | Director | Retired | 2025-03-27 |
| Alessandro Riva, M.D. | Class III director (member of the Board and the Scientific Committee) | Appointed | 2025-03-27 |
| Felix J. Baker, Ph.D. | Class I director | Appointed | 2024-04-18 |
| Veronica Jordan, Ph.D. | Class I director | Resigned | 2024-04-18 |
| Stephen Sands | Class III director | Appointed | 2024-02-20 |
| Travis Thompson | Chief Accounting Officer and principal accounting officer | Appointed | 2023-06-23 |
| Lee Kalowski | Chief Financial Officer | Resigned | 2023-06-23 |
| Alethia Young | Chief Financial Officer and principal financial officer | Appointed | 2023-06-23 |
Leadership
- Kevin Lee CEO, Board Member
- Felix J. Baker, Ph.D. Chairman, Board Member
- Pierre Legault Chairman
- Alethia Young CFO
- Travis Thompson CFO, Chief Accounting Officer
- Alistair Milnes COO
- Jennifer Perry COO
- Jennifer Perry, Pharm.D. COO
- Michael Skynner COO, CTO
- Alessandro Riva, M.D. Board Member
- Bosun Hau Board Member
- Carolyn Ng Board Member
- Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP Board Member
- Hervé Hoppenot Board Member
- Janice Bourque Board Member
- Jose-Carlos Gutierrez-Ramos, Ph.D. Board Member
- Michael Anstey Board Member
- Roger Dansey, M.D. Board Member
- Sir Greg Winter Board Member
- Stephen Sands Board Member
- Veronica Jordan Board Member
Key facts
CIK
1761612
CUSIP
088786108
13F (30d)
14 filings
14 filers
Visit website
Investor relations